Abstract
Background Accurate and reliable diagnosis of COVID-19 is essential for effective disease management and public health interventions. SARS-CoV-2 antibody/antigen tests play a crucial role in identifying covid-19 infections and assessing immunity in populations. This systematic review aimed to evaluate the sensitivity, specificity, and accuracy of SARS-CoV-2 antibody tests in diagnosing COVID-19.
Method A comprehensive systematic review of the literature was conducted using prominent scientific databases, including PubMed, Google Scholar, Cochrane, and Scopus to search studies published from January 2020 to May 2023. The review followed the PRISMA-DTA framework to ensure transparency and rigor in the selection and evaluation of studies. The QUADAS-2 tool was utilized to assess study quality and risk of bias. This review was registered on PROSPERO (registration number CRD 42023445695).
Results The pooled sensitivity of SARS-CoV-2 antibody/antigen tests was found to be 73% (95% CI: 60–86), with individual studies reporting a wide range from 30% to 100%. The pooled specificity was 98% (95% CI: 97–100), with values ranging from 85.9% to 100%. The pooled accuracy was 88%, showing variation from 50% to 100% across different studies.
Conclusion This review highlights the moderate to high sensitivity and specificity of SARS-CoV-2 antibody/antigen tests for COVID-19 diagnosis. The substantial variability in test performance necessitates the standardization of testing protocols and further research to improve accuracy and reliability. These findings offer valuable insights for clinical decision-making and the formulation of effective public health strategies related to COVID-19 diagnosis.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research did not receive any specific grant from funding agencies in the public, commercial, or not for profit sectors
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This review was registered on PROSPERO (registration number CRD 42023445695).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced or analyzed in the study is provided in this article. Additional related data can be requested from the corresponding author.
